UltraPlex
UltraPlex pioneering sustainable and cost-efficient liposome-based RNA therapeutics delivery.
Status:
Pre-business
SDGs:
Good health and well-being
Industry:
Life science and medical
Impact:
Quality of life
Origin:
Research to Business
School:
School of Science
Established:
2025
The UltraPlex project develops a next-generation liposome-based drug delivery system for RNA therapeutics that is sustainable, cost-efficient, and scalable for pharmaceutical applications. Traditional liposomal formulations face challenges such as high production costs, solvent dependency, material waste, and therapeutic molecule encapsulation inefficiency issues, limiting their commercial viability. UltraPlex addresses these challenges by integrating green chemistry, nanotechnology, and focused ultrasound principles to create an eco-friendly and efficient drug delivery platform.
Contact
Christopher Fogarty
Business Developer
Read more about innovation services
News from innovation ecosystem
Turn your idea into impact with 100STARTUPS, October 21-22
In October, we bring together students, job seekers, creators, dreamers, and future founders to learn the right tools and methods to start building what you always wanted to bring to life.
The Sustainability Highlights brochure compiles the sustainability actions promoted at the School of Business
The brochure provides a clear picture of what has already been achieved and which issues we will continue to promote
Holdix donates one million euros to Aalto University’s innovation and entrepreneurship activities
With the help of donation, researchers assess the business potential of their work and build capabilities for commercialising research-driven inventions.